{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:10:29Z","timestamp":1768317029824,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two elvitegravir\/cobicistat\u2010based therapies combined with emtricitabine\/tenofovir disoproxil fumarate (EVG\/c\/FTC\/TDF) or emtricitabine\/tenofovir alafenamide fumarate (EVG\/c\/FTC\/TAF) are currently available for HIV patients. This study evaluated the modifications in the lipid profile of patients who received these treatments in the last three years at our institution. A retrospective observational study in HIV\u2010infected patients who received EVG\/c\/FTC\/TDF or EVG\/c\/FTC\/TAF from January 2015 to January 2018 at a reference hospital in northwestern Spain was carried out. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed using SPSS software. A total of 384 EVG\/c\u2010based therapies were initiated during the study period, 151 EVG\/c\/FTC\/TDF and 233 EVG\/c\/FTC\/TAF. A significantly negative influence in all the lipid profile parameters in experienced patients and total cholesterol (TC), and LDL\u2010C in na\u00efve patients were observed after 48\u00a0weeks of treatment with EVG\/c\/FTC\/TAF, while these parameters remained stable in the EVG\/c\/FTC\/TDF group. During follow\u2010up, a greater proportion of patients had lipid levels above the normal range (63.1% TC, 56.2% LDL\u2010C) and new lipid\u2010modifying drugs were prescribed (11.9%) in the EVG\/c\/FTC\/TAF group. The number of cardiovascular risk factors (OR 1.66 [95% CI 1.01\u20102.72]; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.043) was recognised as an independent predictor of lipid\u2010lowering prescription for patients treated with both EVG\/c\/FTC\/TDF and EVG\/c\/FTC\/TAF. For patients treated with EVG\/c\/FTC\/TAF, the mean total cholesterol to HDL ratio in the first 48\u00a0weeks of the study treatment was associated with a higher likelihood of lipid\u2010lowering prescription in multivariate analysis (OR 1.6 [95% CI 1.12\u20102.52]; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.011). Significant changes in lipid profile have been observed in patients who have received EVG\/c\/FTC\/TAF. It was necessary to prescribe almost twice the number of lipid\u2010lowering drugs to patients who received EVG\/c\/FTC\/TAF (11.9%) vs EVG\/c\/FTC\/TDF (4.7%).<\/jats:p>","DOI":"10.1111\/bcpt.13161","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T16:44:37Z","timestamp":1541177077000},"page":"479-490","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV\u2010infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine"],"prefix":"10.1111","volume":"124","author":[{"given":"Purificaci\u00f3n","family":"Cid\u2010Silva","sequence":"first","affiliation":[{"name":"Division of Clinical Virology Biomedical Research Institute of A Coru\u00f1a (INIBIC)\u2010Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS, University of A Coru\u00f1a (UDC) A Coru\u00f1a Spain"},{"name":"Service of Pharmacy Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Fern\u00e1ndez\u2010Bargiela","sequence":"additional","affiliation":[{"name":"Service of Pharmacy Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Margusino\u2010Frami\u00f1\u00e1n","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology Biomedical Research Institute of A Coru\u00f1a (INIBIC)\u2010Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS, University of A Coru\u00f1a (UDC) A Coru\u00f1a Spain"},{"name":"Service of Pharmacy Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanesa","family":"Balboa\u2010Barreiro","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biostatistics Unit Biomedical Research Institute of A Coru\u00f1a (INIBIC)\u2010Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS, University of A Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Mena\u2010De\u2010Cea","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology Biomedical Research Institute of A Coru\u00f1a (INIBIC)\u2010Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS, University of A Coru\u00f1a (UDC) A Coru\u00f1a Spain"},{"name":"Service of Infectious Internal Medicine Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad","family":"L\u00f3pez\u2010Calvo","sequence":"additional","affiliation":[{"name":"Service of Infectious Internal Medicine Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"V\u00e1zquez\u2010Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Service of Infectious Internal Medicine Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mart\u00edn\u2010Herranz","sequence":"additional","affiliation":[{"name":"Service of Pharmacy Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"M\u00edguez\u2010Rey","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology Biomedical Research Institute of A Coru\u00f1a (INIBIC)\u2010Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS, University of A Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Poveda","sequence":"additional","affiliation":[{"name":"Group of Virology and Pathogenesis Galicia Sur Health Research Institute (IIS Galicia Sur)\u2010Complexo Hospitalario Universitario de Vigo, SERGAS\u2010UVigo  Vigo Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Castro\u2010Iglesias","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology Biomedical Research Institute of A Coru\u00f1a (INIBIC)\u2010Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS, University of A Coru\u00f1a (UDC) A Coru\u00f1a Spain"},{"name":"Service of Infectious Internal Medicine Universitary Hospital of A Coru\u00f1a (CHUAC), SERGAS A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1446653"},{"key":"e_1_2_6_4_1","first-page":"E17","volume":"6","author":"McGettrick P","year":"2018","journal-title":"Ageing with HIV. Healthcare"},{"key":"e_1_2_6_5_1","first-page":"120","article-title":"The challenge of aging and pharmacoterapeutic complexity in the HIV + patient","volume":"42","author":"Morillo\u2010Verdugo R","year":"2018","journal-title":"Farm Hosp"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2626-z"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042909-093756"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-018-0708-z"},{"key":"e_1_2_6_9_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents. Department of Health and Human Services May 30 2018.http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf. Accessed on 03 August 2018."},{"key":"e_1_2_6_10_1","unstructured":"Panel Members of European AIDS Clinical Society (EACS).European Guidelines for treatment of HIV\u2010positive adults in Europe version 9.0. EACS October 2017.http:\/\/www.eacsociety.org\/files\/guidelines_9.0\u2010english.pdf. Accessed on 03 August 2018."},{"key":"e_1_2_6_11_1","unstructured":"Panel de expertos de GeSIDA y Plan Nacional sobre el Sida.Documento de consenso de GESIDA\/Plan nacional sobre el sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2018). SEIMC January 2018.http:\/\/gesida-seimc.org\/wp-content\/uploads\/2018\/01\/gesida_TAR_adultos_v3-1.pdf. Accessed on 03 August 2018."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.191"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815acab8"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005387"},{"key":"e_1_2_6_16_1","first-page":"573","article-title":"Use study of tenofovir DF in highly active anti\u2010retroviral therapy","volume":"23","author":"Fern\u00e1ndez Lis\u00f3n LC","year":"2006","journal-title":"An Med Interna"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad8b4"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328341f925"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005146"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001350"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001344"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13059"},{"key":"e_1_2_6_28_1","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Version 2.0 November 2014. Services Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health US Department of Health and Human."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"e_1_2_6_30_1","first-page":"133","article-title":"Management of long\u2010term complications of HIV disease: focus on cardiovascular disease","volume":"25","author":"Currier JS","year":"2018","journal-title":"Top Antivir Med"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30061-4"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0304"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181acb65f"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000581"},{"key":"e_1_2_6_35_1","first-page":"90","article-title":"Influence of pharmacotherapy complexity on compliance with the therapeutic objectives for HIV+ patients on antiretroviral treatment concomitant with therapy for dyslipidemia. INCOFAR Project","volume":"40","author":"Jim\u00e9nez Gal\u00e1n R","year":"2016","journal-title":"Farm Hosp"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.13161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13161","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T10:56:44Z","timestamp":1694429804000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/bcpt.13161"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13161","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]},"assertion":[{"value":"2018-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}